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Aim: To investigate the effects of inspiratory muscle training (IMT) on functional capacity and
balance, respiratory and peripheral muscle strength, pulmonary function, dyspnea, fatigue,
depression, and quality of life in heart failure patients.
Methods: A prospective, randomized controlled, double-blinded study. Thirty patients with
heart failure (NYHA II-III, LVEF<40%) were included. Sixteen patients received IMT at 40% of
maximal inspiratory pressure (MIP), and 14 patients received sham therapy (15% of MIP) for
6 weeks. Functional capacity and balance, respiratory muscle strength, quadriceps femoris
muscle strength, pulmonary function, dyspnea, fatigue, quality of life, and depression were
evaluated.
Results: Functional capacity and balance, respiratory and peripheral muscle strength, dys-
pnea, depression were significantly improved in the treatment group compared with controls;
quality of life and fatigue were similarly improved within groups (p < 0.05). Functional
capac i t y (418.59  123 .32 to 478 .56  131 .58 m, p < 0 .001 ) , re sp i ra to ry
(MIP Z 62.00  33.57 to 97.13  32.63 cmH2O, p < 0.001) and quadriceps femoris muscle
strength (240.91  106.08 to 301.82  111.86 N, p < 0.001), FEV1%, FVC% and PEF%, functional
balance (52.73  3.15 to 54.25  2.34, p < 0.001), functional dyspnea (2.27  0.88 to
1.07  0.79, p < 0.001), depression (11.47  7.50 to 3.20  4.09, p < 0.001), quality of life,
fatigue (42.73  11.75 to 29.07  13.96, p < 0.001) were significantly improved in theperformed: Hacettepe University, Faculty of Health Sciences, Department of Physiotherapy and
iversity, Faculty of Health Sciences, Department of Physiotherapy and Rehabilitation,
, 06500 Besevler, Ankara, Turkey. Tel.: þ90 312 2162628; fax: þ90 312 2162636.
hotmail.com (M. Bosnak-Guclu), hulya_arikan@yahoo.ca (H. Arikan), semasavci@yahoo.com
tr (D. Inal-Ince), tulumenerol@yahoo.com (E. Tulumen), kudret.aytemir@hacettepe.edu.tr
r (L. Tokgo¨zoglu).
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1672 M. Bosnak-Guclu et al.treatment group. Respiratory muscle strength (MIP Z 78.64  35.95 to 90.86  30.23 cmH2O,
p Z 0.001), FVC%, depression (14.36  9.04 to 9.50  10.42, p Z 0.011), quality of life and
fatigue (42.86  12.67 to 32.93  15.87, pZ 0.008) were significantly improved in the control
group.
Conclusion: The IMT improves functional capacity and balance, respiratory and peripheral
muscle strength; decreases depression and dyspnea perception in patients with heart failure.
IMT should be included effectively in pulmonary rehabilitation programs.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Heart failure is a complex clinical syndrome manifesting
as inability to supply adequate blood flow throughout the
body due to any structural or functional cardiac abnor-
mality.1 The most common complaints are exercise intol-
erance, dyspnea, and fatigue in patients with heart
failure. Mechanisms are multifactorial and interacting
each other in patients with heart failure. Dominant cata-
bolic process caused by left ventricular impairment, leads
to respiratory and skeletal muscle myopathy. Increased
ergoreflex activation caused by myopathy results in
exercise intolerance.2
It is clearly stated that respiratory muscle weakness is
prevalent and contributes to exercise intolerance in
patients with heart failure.3 Abnormal increase in work of
breathing due to excessive ventilatory response4 may
probably contributes to dyspnea and exercise intolerance.
In addition it has been suggested that central nervous
system’s perception of inspiratory output, increased by
a signal produced by reduced inspiratory muscle strength,
increases dyspnea.5 IMT may decrease work of breathing,
metabolic costs of breathing and perception of nervous
system’s perception of inspiratory output, so that dyspnea
and exercise capacity would be improved.
Peripheral muscle weakness also results in exercise
intolerance,2 and a study suggested that blood flow is
distributed from respiratory to locomotor muscles during
unloaded breathing.6 IMT may increase blood flow to
peripheral muscles so that, peripheral muscle strength and
also exercise capacity should be improved. To our knowl-
edge no study investigated the effects of IMT on peripheral
muscle strength. Fatigue is a frequent symptom among
heart failure due to impaired cardiac pump is responsible
for inadequate oxygen delivery and build up waste products
from anaerobic metabolism.7 To our knowledge no study
investigated the effects of IMT on fatigue perception.
Depression is highly prevalent in heart failure and predicts
worse outcomes in terms of hospital readmissions rates,
functional status.8 Reduced physical activity enhances the
peripheral and musculoskeletal pathological changes that
are known to worsen heart failure symptoms and accelerate
disease progression.9 Evidence in literature supports that
depression and physical function reinforcing and changing
in the same direction over time together; when one
worsens, the other also worsens.10 Interventions like IMT
may concurrently improve physical function and may also
reduce depression and improve clinical outcomes and
quality of life. No study investigated the effects of IMT on
depression in patients with heart failure until now.Advances in understanding the pathophysiology of heart
failure are extending the scope and applicability of
pulmonary rehabilitation in heart failure. Although num-
bers of studies supporting the potential benefits of IMT in
different patient population, it is not generally considered
in clinical practice in patients with heart failure. This may
be partially due to the lack of enough evidence supporting
the beneficial effects of IMT in heart failure population. In
the literature, evidences are growing that IMT improves
functional capacity, oxygen consumption, dyspnea and
quality of life in patients with heart failure.11e16 However,
results were differentiated due to the differences in study
designs, patient selection, assessment tools and training
protocols and also there is no study investigating the
benefits of IMT on fatigue, depression, peripheral muscle
strength and balance.
Therefore, we designed a randomized controlled and
double-blinded study to investigate the effects of IMT on
functional capacity, respiratory and peripheral muscle
strength, functional balance, pulmonary function, dyspnea,
depression, fatigue, and quality of life in patients with
heart failure.
We hypothesized that IMT improves functional capacity,
respiratory and peripheral muscle strength, functional
balance, pulmonary function, quality of life, alleviates
dyspnea and fatigue perception, decreases depression in
patients with heart failure.
Materials and methods
Patients
Thirty-six patients with heart failure referred to Hacettepe
University Faculty of Health Sciences, Department of
Physiotherapy and Rehabilitation between June 2007 and
November 2009, were included in this study. The inclusion
criteria were; being clinically stable, left ventricular
ejection fraction (LVEF) below 40%, New York Heart Asso-
ciation (NYHA) Class II and III, and no change in medications
over three months. Patients with cardiac pacemaker were
included after 6 weeks after implementation. The exclusion
criteria were; having acute myocardial infarction, cognitive
disorders, complex arrhythmias, uncontrolled hyperten-
sion, angina pectoris, recent viral infections (6 months prior
to study), orthopedic problems, and rheumatologic
diseases. The study was approved by the Ethics Committee
of the Hacettepe University, and performed in accordance
with the Declaration of Helsinki. Written informed consent
was obtained from all patients to participate in the study.
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A prospective, randomized controlled, double-blinded
study was performed. Prior to randomization, all patients’
clinical evaluation and echocardiographic measurements
were done by a cardiologist. Patients were randomly allo-
cated to either a treatment group (18 patients) or a control
group (18 patients). A computer-based program was used
for randomization. All patients were taking optimal medical
treatment. The treatment group received IMT, and control
group received sham IMT for 6 weeks. Before and after the
IMT, functional capacity, respiratory and peripheral muscle
strength, functional balance, pulmonary function, dyspnea
and fatigue perception, quality of life, and depression
severity were evaluated.
Blinding
Neither the investigator collected pre-and post IMT data,
nor the patients were aware of whether they had been
allocated to treatment or control group. Patients’ evalua-
tion and treatments were performed by different physio-
therapists. Treatment and controls were trained at
different places and times.
Measurements
Pulmonary function tests
Spirometric measurement was performed using a portable
spirometry (Spirobank MIR, Italy) according to the guide-
lines of the American Thoracic Society.17 Forced expiratory
volume in 1 s (FEV1), forced vital capacity (FVC), and peak
expiratory flow (PEF) were expressed as the percentages of
the predicted values.18
Respiratory muscle strength
Maximal inspiratory pressure (MIP) and maximal expiratory
pressure (MEP) were assessed using an electronic pressure
transducer (MicroRPM; Micromedical, Kent, UK). The MIP
was measured at residual volume, and MEP was measured
from total lung capacity, according to Black and Hyatt.19,20
Reference values were used for the comparison.20
Peripheral isometric muscle strength
Quadriceps femoris isometric strength was measured in
a sitting position from non-dominant side, using a hand-
held dynamometer (JTECH Power Track Commander II,
USA). Muscle strength testing was done according to Bee-
nakker et al.21 Values were expressed as the percentage
of predicted values for healthy, sex and age matched
subjects.22
Functional capacity
Six-minute walk test (6MWT) was applied in a 30-m unob-
structed corridor. Patients and controls were instructed to
walk their own pace but to cover as much meter as possible
within 6 min. Each minute standardized encouragement
was given to the patients. Patients were allowed to stop
and rest during test, but were instructed to go on walking as
soon as they were able to do so.23 Heart rate was monitored
using a Polar heart rate monitor (PE3000 Polar Electro,Finland) during the test. Maximum heart rate values ach-
ieved during the tests were recorded. Modified Borg Dysp-
nea Scale was used before and after the 6MWT. The 6MWT
distance expressed as percentage of the predicted values.24
The 6MWT was repeated two times. Patients were rested
30 min between the two tests, and the highest distance was
recorded.
Balance
Berg Balance Scale was used to evaluate functional
balance, 14 item scale, each scored 0 (lowest level of
function) to 4 (highest level of function), total score 56.25
Fatigue
Fatigue was evaluated using Turkish version of Fatigue
Severity Scale.26 It is a self- administered questionnaire,
consisting of nine items. Patients were asked to rate their
level of agreement with the nine statements, each item
scored 0 to 7, (0: strong disagreement, 7: strong agree-
ment). A score of 36 and above (out of a maximum of 63)
indicated the presence of significant fatigue.27
Depression
Depression severity was evaluated using Turkish version of
Montgomery Aˆsberg Depression Rating Scale.28 The scale
consisting of 10 items, scores for each item ranging from
0e6. Low scores implied mild depression whereas high
scores implied severe depression.29
Dyspnea
Modified Medical Research Council dyspnea scale was used
to evaluate dyspnea severity during activity. Levels of
dyspnea are graded 0 (absence of dyspnea during strenuous
exercise), to 4 (dyspnea during daily activities).30
Quality of life
Quality of life was assessed using Turkish version31 of the
SF-36. The SF-36 is a generic measure, consisting of eight
subscales and 36 items. These subscales are physical
functioning, role-physical, role-emotional, vitality, mental
health, social functioning, bodily pain, general health. All
subscales ranges from 0 (worst possible) to100 points (best
health). Global physical and mental health scores were
calculated using subscales.32
Inspiratory muscle training protocol
Before IMT, patients were taken in one-week familiariza-
tion period and instructed to learn breathing adequately.
After, training workloads were adjusted to lower loads
(20e30% of MIP for treatment group and free of pressure for
control group) and patients were instructed to maintain
adequate inspiration and expiration while using Threshold
IMT device (Respironics, USA). As soon as the patients
managed to maintain adequate workload, IMT was started.
Treatment group received IMT at 40% of MIP, and training
loads were adjusted to maintain 40% of the MIP, weekly. MIP
was measured at supervised session each week, and 40% of
measured MIP value was the new training workload. Control
group received sham IMT at fixed workload, 15% of MIP. Both
groups trained for 30 min-per day, 7 days per week, for 6
weeks. Once a day at each week, patients’ heart rate,
blood pressure and breathing frequency were monitorized
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the treatment group. Six sessions were performed at home
and 1session was supervised at the rehabilitation depart-
ment in both groups. In total, 8 sessions were supervised (2
sessions in familiarization period, and 1 session at each
week during 6 weeks). Patients were instructed to maintain
diaphragmatic breathing, and try to maintain 10-15 breaths
and rested 5e10 s between breaths. As soon as the patients
managed; they were encouraged to maintain 25-30 breaths
at each workload. All patients wore nose-clip during
sessions. IMT diaries were checked weekly. Patients were
checked by phone calls two times a week, whether they are
doing IMT in a right way. Total minute spent during training
period for each patient was calculated based on their
reports written on diaries. Patients were told not to exer-
cise or do physical activity over their normal routine during
the study period.
Statistical analysis
All statistical analyses were performed using SPSS 15.0
statistical package (SPSS Inc., USA). Based on the results of
previous study,11 we estimated that a sample size of 15
patients in each group would have a power of 80% to detect
54 m difference in functional capacity for an a value of
0.05. Data normality was tested using KolmogoroveSmirnov
test. Data were expressed as mean (SD) unless otherwise
stated. Baseline characteristics of the two groups were
compared using a Student t-test and differences between
groups were reported as mean difference and 95%CI.
Nominal data were compared using Chi-square test.
ANCOVA was performed to compare the change in lung
function, respiratory and peripheral muscle strength, 6MWT
distance, dyspnea, fatigue, depression, and quality of life
between the two groups accounting for any change in
baseline variables. Manually adjusted post-hoc comparisons
were done using the Bonferroni test. Statistical power and
effect size were calculated using the results of 6MWT.
Training efficiency, expressed as the mean improvement in
MIP per hour of time spent training (expressed as
cmH2O.h
1), was calculated. A p-value 0.05 was consid-
ered as statistically significant.Results
Between June 2007 and November 2009, 216 patients with
heart failure were screened for the study. 180 patients
were excluded because of various reasons (Fig. 1). Thirty-
six patients were randomly assigned to either treat-
ment or control group. Thirty patients (24 M, 6 F,
LVEF Z 34.68  7.41%) were completed the study, 16
patients in the treatment group, and 14 patients in the
control group. 20 patients (66.7%) were in NYHA Class II and
10 patients (33.3%) in Class III. All patients were taking
optimal medical therapy including beta blockers, diuretics,
digoxin, and angiotensin-converting enzyme inhibitors. No
significant alterations were done in medication during the
study in either group. All patients tolerated IMTwithout any
complaints, and no adverse effects occurred during evalu-
ation and treatment. No significant changes were detected
in vital signs or electrocardiographic findings in patients
with pacemaker during first and following sessions. Fivepatients (31.25%) in the treatment group, seven patients
(50%) in the control group had no respiratory muscle
weakness (MIP>70% of predicted). Treatment group
received mean 37.45  4.26% of MIP, control group received
fixed 15% of MIP during threshold loaded 42 sessions.
Adherence to training regimen was high in both groups.
There was no significant difference between the groups in
terms of time spent during IMT; treatment group spent
1226.25  64.69 min (97.32  5.13% of expected), control
group spent 1208.57  91.47 min (95.92  7.26% of
expected) (p < 0.05). Two patients in the treatment group
received IMT at 30e35% of MIP because of the Threshold IMT
device, has no pressures over 42 cmH2O.Baseline characteristics
There were no significant differences between the two
groups in baseline demographic characteristics of age,
gender, NYHA functional class, weight, height, body mass
index (BMI), medication, smoking, pacemaker type, and
etiology of heart failure (Table 1) (p > 0.05). The etiology
of the heart failure was predominantly ischemic in both
groups. The BMI scores were over 25 kg/m2 in 10 patients
(62.5%) in the treatment group and nine patients (64.3%) in
the control group. Both groups were statistically similar in
terms of LVEF, pulmonary function, peripheral and respi-
ratory muscle strength, 6MWT distance, balance, dyspnea
and fatigue perception, depression severity, and quality of
life (Table 1e4) (p > 0.05).
Inspiratory and expiratory muscle strength
MIP, MEP, %MIP and %MEP were significantly improved in
both groups. Improvements in MIP (20.14 cmH2O, 95%
CI Z 10.19 to 30.07 cmH2O) and MEP (13.83 cmH2O, 95%
CIZ 3.72 to 24.06 cmH2O) were greater in the treatment
group as compared with control group (p < 0.05, Table 2).
In the treatment group MIP (33.83 cmH2O, 95%CIZ 27.85 to
40.51 cmH2O), MEP (22.38 cmH2O, 95%CI Z 15.47 to 29.29
cmH2O) and %MIP (41.39%, 95%CI Z 30.66e52.12%), %MEP
(12.96%, 95%CI Z 8.81e17.1%) significantly increased. In
the control group, MIP (13.69 cmH2O, 95%CIZ 6.54 to 20.85
cmH2O), MEP (8.49 cmH2O, 95%CI Z 1.09 to 15.89 cmH2O)
and %MIP (14.69%, 95%CI Z 3.19e26.17%), and %MEP
(4.25%, 95%CI Z 0.19e8.68%) significantly increased
(p < 0.05, Table 2). The IMT resulted in a mean improve-
ment of MIP; 1.72  0.76 cmH2O.h1 in the treatment
group, 0.63  0.62 cmH2O.h1 in the control group
(p < 0.001).
Functional capacity
The distance covered during 6MWT (47.131 m, 95%
CIZ 25.78e68.49m, CohendZ0.43) and%6MWT (7.85%, 95%
CI Z 4.39e11.31%) significantly improved in the treatment
group compared with control group (p < 0.05). The distance
covered during 6MWT and %6MWT significantly increased
(60.37 m, 95%CI Z 45.89e74.84 m; 9.80%, 95%
CIZ 7.44e12.16%, respectively) in the treatment group; in
contrast, no significant improvements were found in the
control group (13.24m, 95%CIZ2.25e28.72m; 1.95%, 95%
CIZ 0.57e4.47% respectively) (Table 3, Figs. 2e5). Func-
tional capacity was also improved >54 m in four patients
Assessed for eligibility (n=216)
Excluded (n=180)
Not meeting inclusion criteria (n=90)
Declined to participate (n=48)
Logistic problems (n=42)
Randomized (n=36)
Received allocated intervention (n=18)Received allocated intervention (n=18)
Lost to follow-up (pulmonary infection) (n=1)
Discontinued intervention (moved to another city) (n=1)
Lost to follow-up (sudden cardiac death) (n=1)
Discontinued intervention (didn’t want to) (n=3)
Control group 
Analyzed (n=14)
Treatment group
Analyzed (n=16)
Figure 1 Flow diagram of the inspiratory muscle training.
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group. No significant changewas observed inmaximumheart
rate within and between the groups (Table 3).
Peripheral muscle strength
Improvement in quadriceps femoris muscle strength
(48.47 N, 95%CI Z 5.55e91.39 N) and the %quadriceps
femoris muscle strength (14.11%, 95%CI Z 1.41e26.81%)Table 1 Baseline demographic characteristics of treatment and
Treatment group Contro
Characteristics Mean  SD Mean 
Age, y 69.50  7.96 65.71 
Male/female, n 12/4
(75%/25%)
12/2
(85.71
NYHA II/III, n 11/5
(68.75%/31.25%)
9/5
(64.29
LVEF, % 33.43  7.23 36.11 
Weight, kg 72.34  13.56 70.20 
Height, cm 164.50  10.19 167.14
BMI, kg/m2 26.76  4.30 25.08 
Smoking, pack-years 34.89  32.01 48.59 
Smoking (non/ex-smoker), n (%) 9/7 (56.25%/43.75%) 11/3 (7
Medication
ACE-I, n (%) 14 (87.5%) 12 (85.
Diuretics, n (%) 11 (68.8%) 8 (57.1
Digoxin, n (%) 14 (87.5%) 13 (92.
Beta blockers, n (%) 14 (87.5%) 12 (85.
Pacemaker type
ICD, n (%) 8 (50%) 5 (35.7
Biventricular, n (%) 2 (12.5%) 3 (21.4
Ischemic/non-ischemic, n (%) 14/2 (87.5%/12.5%) 12/2 (8
LVEF: left ventricular ejection fraction, ACE-I: Angiotensin-convertingwere significantly higher in the treatment group compared
with control group (p < 0.05). Quadriceps femoris muscle
strength (62.96 N, 95%CI Z 34.66e91.26 N), and %quadri-
ceps femoris muscle strength were significantly improved
(18.42%, 95%CI Z 10.24e26.60%) in the treatment group
(p < 0.05), no significant chances were observed (14.49 N,
95%CI Z 16.89e45.88 N; 4.31%, 95%CI Z 4.81e13.42%,
respectively) in the control group (p > 0.05, Table 2).control groups.
l group
SD Mean difference %95 CI p
10.52 3.79 3.14 to 10.71 0.27
%/14.29%)
0.66
%/35.71%)
1.00
7.62 2.67 8.23 to 2.89 0.33
11.06 2.14 7.20 to 11.48 0.64
 8.38 2.64 9.69 to 4.40 0.45
3.17 1.68 1.18 to 4.54 0.24
33.72 13.70 44.84 to 17.44 0.37
8.57%/21.43%) 0.26
7%) 1.00
%) 0.51
9%) 1.00
7%) 1.00
1%) 0.61
3%)
5.7%/14.3%) 1.00
enzyme inhibitors, ICD: Implantable cardioverter-defibrillator.
Table 2 Effects of inspiratory muscle training on pulmonary function, respiratory and peripheral muscle strength.
Treatment group Control group
Before After Group
difference
Before After Group
difference
Treatment
affect
Characteristics Mean  SD Mean  SD p Mean  SD Mean  SD p p
FEV1, % 84.57  15.99 89.57  14.55 0.024 86.75  20.75 89.66  19.97 0.67 0.56
FVC, % 92.07  15.04 102.50  15.94 0.001 91.54  14.69 97.62  15.27 0.023 0.46
FEV1/FVC 71.15  10.28 69.01  11.27 0.11 71.83  8.28 74.27  5.85 0.073 0.020
PEF, % 73.57  21.89 78.29  29.06 0.049 84.08  18.88 87.62  17.19 0.25 0.57
MIP, cmH2O 62.00  33.57 97.13  32.63 <0.001 78.64  35.95 90.86  30.23 0.001 <0.001
MIP, % predicted 66.39  28.09 108.84  37.11 <0.001 78.41  26.26 91.88  18.74 0.014 0.002
MEP, cmH2O 102.63  55.24 125.06  56.16 <0.001 115.86  43.21 124.70  50.38 0.026 0.009
MEP, % predicted 54.33  21.85 67.35  22.89 <0.001 57.78  18.01 61.96  18.59 0.060 0.007
Quadriceps femoris,
N
240.91  106.08 301.82  111.86 <0.001 291.89  102.85 308.89  133.02 0.34 0.029
Quadriceps femoris,
% predicted
70.29  22.99 88.86  22.69 <0.001 86.36  18.11 90.49  25.17 0.33 0.031
Berg Balance Scale
(0-56)
52.73  3.15 54.25  2.34 <0.001 54.77  3.19 55.00  3.23 0.17 0.034
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; PEF: peak expiratory flow; MIP: maximal inspiratory pressure; MEP:
maximal expiratory pressure.
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Functional balance was significantly improved in the
treatment group compared with control group (0.94, 95%
CI Z 0.08 to 1.79, p < 0.05). There was a significant
increase in balance scores within the treatment group
(1.36, 95%CI Z 0.79 to 1.94, p < 0.05), in contrast to
control group (0.43, 95%CI Z 0.19 to 1.04, p > 0.05)
(Table 2).
Pulmonary function
There were no significant differences in FEV1%, FVC% and
PEF% between the groups after IMT (p > 0.05). Change in
FEV1/FVC was significantly different between the groups,
attributed to significant higher increase in FVC% in the
treatment group than the control group (p < 0.05), noTable 3 Effects of inspiratory muscle training on functional ca
Treatment group
Before After Group
differenc
Characteristics Mean  SD Mean  SD p
6MWT, m 418.59  123.32 478.56  131.58 <0.001
6MWT, % predicted 69.19  16.59 79.00  17.93 <0.001
Maximum heart
rate, %
65.50  10.45 68.26  10.09 0.43
D Heart rate,
beats/min
28.20  13.32 32.60  9.98 0.32
D Borg Dyspnea 2.42  1.73 1.42  1.31 0.025
Modified Medical
Research Council
Scale (0-4)
2.27  0.88 1.07  0.79 <0.001
6MWT: 6 min walk test.significant change was found in FEV1/FVC within groups.
FEV1% and PEF% were significantly increased after IMT in
the treatment group (p < 0.05, Table 2).
Dyspnea
Dyspnea perception during activity significantly alleviated
more in the treatment group as compared with control
group (0.92, 95%CI Z 1.22 to 0.62, p < 0.05). Func-
tional dyspnea significantly improved not only in the
treatment group (1.17, 95%CIZ 1.37 to 0.96), but also
in the control group (0.25, 95%CI Z 0.46 to 0.04)
(p < 0.05, Table 3). No significant difference was found in
dyspnea perception, evaluated using Modified Borg Dyspnea
Scale, between groups; nonetheless dyspnea was signifi-
cantly decreased within groups (Table 3).pacity and dyspnea.
Control group
e
Before After Group
difference
Treatment
affect
Mean  SD Mean  SD p p
462.31  133.59 475.99  135.79 0.091 <0.001
71.16  16.17 73.09  15.68 0.13 <0.001
68.75  10.85 65.54  9.39 0.39 0.25
33.62  16.65 29.23  12.61 0.41 0.21
2.64  1.21 1.77  1.13 0.059 0.82
1.93  0.92 1.71  0.83 0.024 <0.001
Table 4 Effects of inspiratory muscle training on fatigue, depression, and quality of life.
Treatment group Control group
Before After Group
difference
Before After Group
difference
Treatment
affect
Characteristics Mean  SD Mean  SD p Mean  SD Mean  SD p p
Fatigue Severity
Scale (0-63)
42.73  11.75 29.07  13.96 <0.001 42.86  12.67 32.93  15.87 0.008 0.44
Montgomery Aˆsberg
Depression Rating
Scale (0-60)
11.47  7.50 3.20  4.09 <0.001 14.36  9.04 9.50  10.42 0.011 0.054
SF-36 (0-100)
Physical functioning 49.33  29.57 68.67  26.69 <0.001 57.14  27.08 69.64  19.06 0.002 0.47
Role-physical 35.00  42.05 51.67  50.41 0.053 30.36  46.18 57.14  48.47 0.024 0.60
Role-emotional 47.92  50.14 51.11  50.18 0.91 45.24  48.23 59.52  45.63 0.20 0.39
Vitality 56.00  17.02 70.67  19.99 0.001 51.07  25.66 64.64  24.29 0.008 0.68
Mental health 61.07  19.92 76.80  16.58 0.001 64.57  18.29 74.57  18.20 0.009 0.44
Social functioning 62.50  28.74 81.67  18.82 0.001 60.71  22.92 88.39  22.71 <0.001 0.36
Bodily pain 57.33  34.94 87.83  15.72 <0.001 71.79  25.95 87.14  20.76 <0.001 0.39
General health 44.33  26.04 61.33  19.87 0.001 48.57  25.60 62.86  23.51 0.002 0.88
Physical health sum
score (0-100)
46.01  28.03 67.38  24.16 <0.001 51.96  23.41 69.19  22.06 <0.001 0.81
Mental health sum
score (0-100)
57.67  23.61 70.06  20.91 0.004 55.39  24.39 71.78  21.60 0.001 0.68
Inspiratory muscle training in heart failure 1677Fatigue
There was no significant differences in fatigue perception
between groups after IMT (3.78, 95%CIZ 13.59 to 6.03,
p > 0.05) but significant differences were found within
groups; in the treatment group (13.69, 95%CIZ 20.51 to
6.87), and control group (9.91, 95%CI Z 16.96 to
2.85) (p < 0.05, Table 4). There was a significant reduc-
tion in significant fatigue in the treatment group (13
patients [81.25%] to 6 patients [37.5%], p Z 0.02), and in
the control group (12 patients [85.71%] to 6 patients
[42.9%], p Z 0.03).0
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Figure 2 Six minute walk test distance before and after IMT
in the treatment group.Depression
Depression significantly decreased after IMT between
(4.45, 95%CI Z 8.98 to 0.08) and within the groups;
the treatment group (8.77, 95%CIZ 11.89 to 5.65) and
the control group (4.32, 95%CI Z 7.55 to 1.09)
(p < 0.05, Table 4).
Quality of life
Quality of life similarly improved in both groups after IMT.
SF-36 physical functioning, role-physical, vitality, mental
health, social functioning, bodily pain, and general health
domains and also, SF-36 physical and mental health sum
scores were significantly improved within groups after the
IMT (p < 0.05, Table 4).0
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Figure 3 Six minute walk test distance before and after IMT
in the control group.
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Figure 4 Percent predicted 6 min walk test distance before
and after IMT in the treatment group.
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The power of the present study is (1-b) Z 99.2%.
Discussion
The present study demonstrated that, IMT improves func-
tional capacity, respiratory and peripheral muscle strength,
and functional balance; alleviates dyspnea and decreases
depression in patients with heart failure. Additionally,
quality of life and fatigue perception were similarly
improved in groups. In terms of efficacy, a six-week IMT
resulted in improvement in functional capacity with high
study power (99.2%). The present study has adequate sample
size, control group, double-blinding to support the hypoth-
esis. When compared with previous studies, our study has
additional superiorities such as; one-week familiarization
periodwas applied prior to IMT, and patients’ adherencewas
strictlymonitoredbyweekly sessions, diaries andphone calls
during training period and reported. As a result, high degree0
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Figure 5 Percent predicted 6 min walk test distance before
and after IMT in the control group.of adherence to the training protocol yielded positive effects
on investigated outcomes. In addition, this is the first report
offers new information about the effects of IMT on dyspnea
during daily living, depression, quadriceps femoris muscle
strength and functional balance. Increase in inspiratory
muscle strength resulted in clinically important decrease in
dyspnea perception during daily living and depression;
increase in quadriceps femoris muscle strength and func-
tional balance, which are very important outcomes,
affecting exercise capacity and quality of life in patients
with heart failure.Functional capacity
There is growing evidence that IMT improves submaximal
functional capacity in patients with heart failure. Six
studies investigated the effects of IMT on functional
capacity evaluated using 6 or 12-min walk tests.11e16 The
number of sessions per week and total training duration
ranged from 3 to 7 days per week and 10e12 weeks,
respectively. Loadings were applied ranging from 30% to
60% of MIP; 30e90 min for each session in these studies. All
6 studies reported significant improvements in functional
capacity ranging from 6.9% to 29% following IMT. Three of
reported higher,11,12,14 two reported lower increase15,16 in
6MWT distance compared with our study. IMT were applied
for 30 min-per day, 7 days per week, for 6 weeks; the
distance covered during 6MWT (59.97  28.05 m, 14.5%)
and %6MWT (9.11%) increased after the IMT in our study.
However, a small randomized trial failed to demonstrate
improvement in functional capacity using corridor walk
test.33 In consistent with previous controlled,11e16
randomized11,13 and blinded14 studies, the present study,
the second randomized controlled double-blinded study
proved that IMT improves functional capacity. Although all
studies reported improvement in 6MWT distance only Dal-
l’Ago et al.14 and we had calculated the adequate sample
size needed. Dall’Ago et al. reported higher improvement
than the present study; 42 h of IMT resulted in 22.5%
increase in 6MWT distance following 21 h of IMT; 6MWT
distance increased by 14.5% in our study. Longer training
frequency and duration may contribute to further
improvement in functional capacity, but there is still no
consensus about the optimal IMT program including inten-
sity, frequency and duration in patients with heart failure.
Our findings as an important evidence supporting the
current literature that IMT improves functional capacity in
patients with heart failure, suggest that IMT should be
implemented in the pulmonary rehabilitation programs.
Inspiratory and expiratory muscle strength
Prior studies demonstrated that IMT results in significant
improvement in MIP ranging from 31.7% to 115% with and
without respiratory muscle weakness in patients with heart
failure.11e16 In accordance with these studies MIP was
improved in our study. Previous studies have reported
substantially lower improvement in MIP than observed in
our study11e13,15,16 although each applied longer duration,
and more rigorous workloads. These differences may be
due to their small sample sizes, uncontrolled study designs,
or application of IMT in patients without respiratory muscle
Inspiratory muscle training in heart failure 1679weakness. Only one study reported higher improvement
than the present study, 42 h of IMT resulted in 115%
increase in MIP.14 In our study, following 21 h of IMT, MIP
increased by 56.66%. This higher increase in MIP than ours
may be due to longer training duration they applied. As
with other skeletal muscles, improvements in strength are
likely to be dose dependent. This was the first study
calculated the training efficiency in literature in patients
with heart failure, IMT resulted in a mean improvement
1.72  0.76 cmH2O.h1 in MIP. For the better comparison of
the effects of IMT on outcomes, training efficiencies should
be calculated as done in this study. Further studies are
needed to compare the effects of IMT in patients with and
without respiratory muscle weakness for a better under-
standing the effects of IMT.
Peripheral muscle strength and functional balance
To our knowledge, we showed for the first time in the
literature that IMT increases quadriceps femoris muscle
strength and functional balance. Increase in quadriceps
femoris muscle may be resulted in improvement in func-
tional balance. A study showed that inspiratory muscle
loading markedly reduces blood flow to resting and exer-
cising limbs in heart failure patients with inspiratory muscle
weakness,34 and IMT improves limb blood flow under
inspiratory muscle loading.35 Quadriceps femoris muscle
strength improvement may be due to increased blood flow
after IMT, and this improvement may be resulted in
decrease in ergoreflex activation and increase in exercise
capacity.2 This hypothesis should be confirmed. Hu¨lsmann
et al. showed that lower extremity muscle strength is an
independent predictor of peak oxygen consumption
(VO2peak) in patients with heart failure.
36
Pulmonary function
We showed marked improvement in FVC%, FEV1%, and PEF%
in the treatment group; and no differences were present
between group comparisons. Change in FEV1/FVC after IMT
was different between the groups, may be attributed to
higher increase in FVC% in the treatment group compared
with control group. There are conflicting results in the
literature related to lung function after IMT in heart failure.
There are findings stating a sufficient increase in FVC%
resulting decrease in FEV1/FVC,
15 and marked increase in
FVC% and FEV1% as compared with controls,
11 and even no
improvements in spirometry.14 Differentiation of findings
from the literature may be due to our patients’ lower
baseline pulmonary function than that of patients included
in other studies or applied different IMT workloads. In
accordance with the literature, we found improvements in
pulmonary function in patients who were trained 40% of
MIP. Higher workloads may be needed to improve pulmo-
nary function in patients with heart failure. For better
understanding of the effects of the IMT on pulmonary
function, dynamic lung volumes should also be evaluated.
Dyspnea
Both groups showed similar improvements in dyspnea,
evaluated using Modified Borg Dyspnea Scale in our study.We
showed a reduction in dyspnea during activities of daily living
after IMT, and higher workloads are needed to improve
dyspnea. Our findings are important because we showed forthe first time the beneficial effects of IMT on functional
dyspnea. Less dyspnea perception during functions may help
patients to be more independent in activities of daily living.
Most of the previous findings showed that IMT improves
dyspnea evaluated using Borg Scale during submaximal and
maximal exercise in patients with heart failure.11,14e16 Two
studies failed to demonstrate these improvements in dysp-
nea probably due to their small sample sizes.12,33 A study
claimed that heart failure initiates cyclical and deleterious
events that impair respiratory muscle function leading to
a ventilator challenge the system is unfit to meet, which
further deteriorates respiratory function.34 IMT may be
cutting this vicious cycle and reducing dyspnea.
Fatigue and depression
In literature for the first time, we investigated the effects of
IMTon fatigue perception. Although fatiguewas alleviated in
both groups, higher IMT workload was not superior to lower
workload. Lower workloads may also have therapeutic
effect in reducing fatigue, thus further studies are needed
investigating the effects of IMT on fatigue. Improvement in
peripheral blood flow,35 quadriceps femoris muscle strength
and functional capacity after IMT may be resulted in
decreased fatigue. Depression among patients with heart
failure is higher than expected among other chronically ill
patients and linked to more severe heart failure symptoms
and worse outcomes.37 Ours was the first study investigating
the effects of IMT on depression in patients with heart
failure, and we showed that IMT decreases depression.
Quality of life
Previous findings of two studies11,14 proved that IMT improves
quality of life evaluated using Minessota Living With Heart
Failure Questionnaire (MLWHF), a disease-specific quality of
life scale. In the present study both groups showed similar
improvement in quality of life measured using a generic
quality of life scale SF-36. Only one domain of SF-36 (role-
emotional) was not improved. This domain investigates the
role limitations in work, and nearly all patients were retired.
Previously studies showed that quality of life improved only
in treatment group, both groups’ quality of life improved in
our study. These different findings may be due to the better
performance in detecting changes in patients who are
elderly and have high comorbidity, including larger number
of health dimensions of SF-36 than MLWHF Questionnaire, as
claimed by Zuluaga et al.38 As many outcomes also improved
in the treatment group, all these improvements may be
resulted in increased quality of life.
In the literature, there is only one case report showed
the beneficial effects of IMT in heart failure patients with
pacemaker.39 In the present study ten patients (62.5%) in
the treatment group, nine patients (64.28%) in the control
group had pacemaker and no adverse effect occurred
during treatment and IMT resulted in improvements in
several outcomes.
Limitations
Some researchers believe that IMT should be applied to the
heart failure patients with inspiratory muscle weakness. We
included 12 patients (40%) without inspiratory muscle
weakness in our study. Three studies11,15,16 done by the
same researchers, proved that IMT improves inspiratory
1680 M. Bosnak-Guclu et al.muscle strength and functional capacity in patients without
inspiratory muscle weakness. New studies should be con-
ducted, to compare the outcomes in heart failure patients
with/without inspiratory muscle weakness for better
understanding the effects of IMT. Despite the documented
benefits of IMT in patients with heart failure, previous and
present study have not been investigated the longer-terms
affects on outcomes and survival. The etiology of the heart
failure was predominantly ischemic; the number of patients
with male gender was high. As in literature, we used
threshold loading 15% of MIP as a sham therapy, thus many
outcomes improved in sham group, may be because of; 15%
of MIP loading may have therapeutic effects. Selecting
lower workloads as a sham therapy will/would be better
while investigating the effects of IMT.
Clinical relevance and future directions
The present study contributes new information to the
knowledge regarding the benefits of IMT on functional
capacity, peripheral muscle strength, functional balance,
quality of life, fatigue and depression. The current results
advice IMT may be beneficial to all outcomes stated. From
a patients’ perspective quality of life, fatigue, dyspnea and
depression are unarguably the most important outcomes.
Since these outcomes improved following IMT, we believe
that this alone justifies the inclusion of IMT to rehabilitation
programs. Achieving to higher training loadswas difficult due
to intolerable dyspnea at the beginning and during the IMT in
patients with heart failure in this study. Most of patients
couldn’t manage to train 40% of MIP at the beginning of IMT,
for this reason a familiarization period should be applied
before IMT. Dyspnea is the most limiting factor of exercise in
patients with heart failure; IMT may be applied before
exercise training to tolerate exercise well. Interval-based
IMT programs may offer opportunity to achieve higher
training loads with dyspnea, although no study has investi-
gated up to now. Based on the result of this study, as no
adverse effect occurred during treatment we suggest that
IMTshould be included as a safe intervention in rehabilitation
programs in heart failure patients with pacemaker.
Conclusions
This randomized, controlled, double-blinded study demon-
strated that, IMT improves functional capacity, respiratory
and peripheral muscle strength, and functional balance;
alleviates dyspnea and decreases depression in patients with
heart failure. Although similar improvements were observed
in quality of life within groups, based on the current litera-
ture we believe that IMT improves quality of life.
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